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Abstract
Introduction:  Poorly  reversible  airﬂow  obstruction  may  or  may  not  be  related  to  smoking.
Objectives:  To  describe  patients  with  severe  obstructive  lung  disease  including  etiology,  imag-
ing, functional  aspects,  systemic  manifestations,  and  the  pattern  of  bronchodilator  response.
Methods:  Sixty-eight  patients  (age  55.9  ±  13.7  years,  FEV1 [forced  expiratory  volume  in  one
second] 31.9  ±  10.2%  predicted)  underwent  spirometry,  evaluation  of  body  mass  composition,
6-minute walk  test,  X-ray,  thorax  high-resolution  CT  scanning,  and  clinical  evaluation.
Results: Of 68  patients  enrolled,  37  had  chronic  obstructive  pulmonary  disease  (COPD)  and
31, extensive  bronchiectasis.  Among  COPD  patients  the  CT  scans  showed  emphysema  in  78.4%,
and bronchiectasis  in  48.6%.  There  were  no  signiﬁcant  differences  between  smokers  and  non-
smokers,  except  for  vital  capacity,  signiﬁcantly  smaller  in  non-smokers  (p  <  0.001).  We  found
29 and  20  volume  responders  (VR)  according  to  Paré  et  al.  (FEV1/FVC  >  1  =  ﬂow  responder  or
<1 =  VR)  and  ATS/ERS  criteria,  respectively.  According  to  Paré  et  al.  criteria,  there  were  18
patients with  FEV1 <  30%  predicted  among  29  VR,  and  12  with  FEV1 <  30%  predicted  among  39
without volume  response  (p  =  0.0101).
Conclusions: In  patients  with  severe  obstruction,  smoking  does  not  appear  to  be  relevant  in
determining  functional  or  systemic  differences,  and  Paré  et  al.  criteria  can  detect  more  VR.
Bronchiectasis  is  a  common  ﬁnding  in  severe  COPD.
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Tomograﬁa  de  tórax
Doenc¸a obstrutiva  grave:  semelhanc¸as  e  diferenc¸as  entre  os  pacientes  fumadores  e
não-fumadores  com  DPOC  e/ou  bronquiectasias
Resumo
Introduc¸ão:  A  obstruc¸ão  das  vias  respiratórias  pouco  reversível  pode  ou  não  estar  relacionada
com o  tabagismo.
Objetivos:  Descrever  pacientes  com  doenc¸a  pulmonar  obstrutiva  grave,  incluindo  etiologia,
aspectos dos  exames  de  imagem,  parâmetros  funcionais,  manifestac¸ões  sistémicas,  e  o  padrão
da resposta  ao  broncodilatador.
Métodos: Sessenta  e  oito  pacientes  (idades  de  55,9±13,7  anos,  FEV1 [volume  expiratório
forc¸ado num  segundo]  31,9±10,2%  previsto)  foram  submetidos  a  espirometria,  avaliac¸ão  da
composic¸ão de  massa  corporal,  teste  de  caminhada  de  6  minutos,  radiograﬁa,  tomograﬁa
computorizadas  (TAC)  de  alta  resoluc¸ão  do  tórax,  e  avaliac¸ão  clínica.
Resultados:  Dos  68  pacientes  inscritos,  37  sofriam  de  doenc¸a  pulmonar  obstrutiva  crónica
(DPOC) e  31  de  bronquiectasias  extensa.  Entre  os  pacientes  com  DPOC,  as  tomograﬁas  computa-
dorizadas  apresentaram  enﬁsema  em  78,4%  e  bronquietasias  em  48,6%.  Não  existiram  diferenc¸as
signiﬁcativas  entre  os  fumadores  e  os  não-fumadores,  exceto  para  a  capacidade  vital,  signiﬁca-
tivamente inferior  nos  não-fumadores  (p  <  0,001).  Encontramos  29  respondedores  de  volume
(RV) pelos  criterios  de  Paré  et  al.  (VEF1/CVF  >  1=  respondedor  de  ﬂuxo,  se  >  1  respondedor  de
volume),  e  20  RV  pelos  criterios  da  ATS/ERS.  De  acordo  com  os  critérios  de  Paré  et  al.,  existiam
18 pacientes  com  FEV1<  30%  previsto  entre  os  29  RV,  e  12  com  FEV1 <  30%  previsto  entre  os  39
sem resposta  a  uma  prova  de  volume  (p  =  0,0101).
Conclusões: Em pacientes  com  obstruc¸ão  grave,  o  tabagismo  não  parece  ser  relevante  na
determinac¸ão de  diferenc¸as  funcionais  ou  sistémicas,  e  os  critérios  de  Paré  et  al.  podem  detetar
mais RV.  A  bronquiectasias  é  uma  descoberta  comum  em  DPOC  grave.
© 2012  Sociedade  Portuguesa  de  Pneumologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
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t  is  quite  clear  nowadays  that  the  most  frequent  cause  of
hronic  and  progressive  airway  disease  that  leads  to  chronic
espiratory  failure  is  Chronic  Obstructive  Pulmonary  Dis-
ase  (COPD)  related  to  tobacco  use.  COPD  is  diagnosed  if
oorly  reversible  airﬂow  obstruction  can  be  demonstrated
y  spirometry  and  the  exposure  to  noxious  gases  is  present.
Poorly  reversible  airﬂow  obstruction  is  not  conﬁned  to
mokers.  Kohansal  et  al.,1 in  a  study  about  the  natural
istory  of  chronic  airﬂow  obstruction,  analyzed  the  Framing-
am  Offspring  cohort,  who  were  followed  for  23  years.  One
hird  of  the  individuals,  who  continued  to  smoke,  devel-
ped  airﬂow  obstruction  during  follow-up.  But  so  did  7.4%
f  never-smoker  males  and  5.6%  of  never-smoker  females.
The  classic  work  of  Fletcher  et  al.2 on  the  natural  history
f  COPD  did  not  include  non-smokers  and  therefore  provides
o  information  about  the  subjects  who  do  not  smoke  but
o  have  chronic  airﬂow  obstruction.  In  the  United  States,
0%  of  the  patients  who  have  obstruction  in  spirometry
nd  20%  of  those  who  die  of  COPD  are  non-smokers.3--6 Few
tudies  have  been  performed  in  this  group  and  little  is  known
bout  its  natural  history  and  clinical  course.
Mucus  hypersecretion,  one  of  the  classic  features  of
OPD,  is  associated  with  exacerbations  and  both  situations
re  related  to  progressive  loss  of  airﬂow.7,8On  the  other  hand,  patients  with  hypersecretion  unre-
ated  to  COPD  may  present  functional  and  clinical  pictures
hat  overlap  with  chronic  bronchitis  associated  with
moking.9
(
u
m
cIn  addition  to  the  symptoms  and  the  spirometric  changes,
ther  similarities  may  exist  between  COPD  and  bronchiec-
asis  from  various  causes:  the  predominant  neutrophilic
nﬂammation,10 the  pattern  of  response  to  bronchodilators
BD),11--13 and  the  ﬁndings  on  imaging  studies.
Having  taken  this  previous  data  into  account  we  decided
o  investigate  the  hypothesis  that  there  are  more  similar-
ties  than  differences  among  patients  with  severe  chronic
ronchial  disease,  regardless  of  whether  they  have  smoking
elated  COPD  or  bronchiectasis  due  to  other  causes.
ethods
atients  who  attended  our  referral  outpatient  clinic  for
hronic  respiratory  failure  and  whose  spirometry  showed  a
re-BD  FEV1 <  50%  of  predicted,  and  FEV1/CVF  <  70%  were
nvited  to  participate  in  this  study.  We  excluded  patients
ith  neuromuscular  diseases,  thoracic  deformities,  restric-
ive  lung  diseases,  pulmonary  vascular  disease  and  those
ho  had  undergone  lung  resection.
The  study  was  approved  by  the  Ethics  Research  Commit-
ee  of  our  institution  and  all  participants  signed  an  informed
onsent  form.
Clinical  data  were  gathered  from  patient  ﬁles.  To  assess
he  degree  of  breathlessness  we  used  the  British  MRC
Medical  Research  Council)  questionnaire.14 All  patients
nderwent  spirometry  before  and  after  the  use  of  for-
oterol  12  mcg  (Foradil®,  Novartis,  Brazil).  Forced  vital
apacity  (FVC)  and  slow  vital  capacity  (VC)  curves  were
Similarities  and  differences  between  smoker  and  non-smoker  patients  15
Table  1  Clinical  features,  spirometric  ﬁndings  and  body  composition  of  patients.
All  patients  (n  =  68)  COPD  patients  (n  =  37)  Patients  with  bronchiectasis  (n  =  31)
Age  (years)  55.9  ±  13.7  59.8  ±  10.7  51.3  ±  15.5
Sex (M/F)  30/38  16/21  14/17
BMI (kg/m2)  24.0  ±  5.2  24.6  ±  5.5  23.2  ±  4.69
FVC (%  predicted)  53.4  ±  15.2  57.0  ±  15.4  49.1  ±  14.1
VC (%  predicted)  59.2  ±  17.4  65.1  ±  17.7  52.1  ±  14.2
FVC (L)  1.82  ±  0.79  1.91  ±  0.74  1.71  ±  0.84
FEV1 (%  predicted)  31.9  ±  10.2  30.2  ±  9.8  34  ±  10.5
FEV1 (L)  0.96  ±  0.39  0.80  ±  0.38  0.93  ±  0.41
Smoking (pack-years) 23.1  ±  34.4 40.7  ±  38.5 2.1  ±  4.8
MM (%  predicted) 89.4  ±  10.5 89.9  ±  10.5 88.9  ±  10.5
All data are expressed as mean ± sd, except sex.
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mass.
performed  using  a  ﬂow  spirometer  (MicroQuark;  COSMED
SRL,  Rome,  Italy)  with  Brazilian  reference  values.15 The  six-
minute  walk  test  (6MWT)  was  performed  by  the  patients  who
had  pulse  oxymetry  (SpO2)  above  90%  at  rest  and  the  proce-
dure  followed  that  proposed  by  ATS.16 Body  mass  index  (BMI)
was  determined  and  the  body  composition  was  assessed  by
the  bioimpedance  technique  (Biodynamics  310,  Seattle,  WA,
USA).  All  tests  were  conducted  during  periods  of  clinical
stability.
To  analyze  the  data  we  ﬁrst  compared  smokers  and  non-
smokers  and  secondly  we  identiﬁed  two  groups  according  to
the  pattern  of  response  to  BD  on  spirometry.
When  comparing  smokers  and  non-smokers  we  set  param-
eters  and  cutoff  values  for  each  variable:  BMI  ≤  21  kg/m2,2,17
MRC  >  1,17 resting  SpO2 <  90%,  use  of  long-term  oxygen  ther-
apy  (LTOT),  FEV1 <  30%  of  predicted,  inspiratory  capacity
(IC)  <  80%  predicted,  6MWD  <  350  m,17 and  a  drop  in  SpO2
during  the  6MWT  (SpO2 ﬁnal--initial)  ≥  4%,  which  were  con-
sidered  signs  of  greater  severity.  For  numerical  variables
[FVC,  VC,  LM  (lean  mass)  in  %  of  predicted,  and  lean-to-
fat  body  mass  ratio  (LM/FM)],  we  calculated  the  mean  and
median  of  the  two  groups.
For  the  analysis  of  BD  response  we  compared  two  crite-
ria:  ATS/ERS  [volume  response  (FVC)  or  ﬂow  response  (FEV1)
200  ml  and  12%],18 and  the  parameters  used  in  the  study  of
Paré  et  al.19 which  were  applied  only  when  the  increase  in
FEV1 or  FVC  post-BD  was  at  least  12%.  According  to  Paré
et  al.  the  volume  response  is  reﬂected  by  the  presence
of  FEV1/CVF  <  1,  and  ﬂow  response,  FEV1/CVF  >  1,
where    means  the  (post-BD  −  pre-BD)  value.19
HRCT  of  the  thorax  was  performed  (sections  1.5--2  mm
thick,  10  mm  intervals,  at  maximum  inspiration  and
expiration)20 and  the  following  CT  ﬁndings  were  analyzed:
presence  of  emphysema  (centrilobular,  paraseptal  and  pan-
lobular),  bronchiectasis,  and  signs  of  disease  in  small
airways  (air  trapping  in  expiratory  scans,  tree-in-bud  pat-
tern,  centrilobular  nodules).  We  also  compared  the  number
of  lobes  affected  by  bronchiectasis  or  emphysema.
Variables  with  normal  distribution  were  analyzed  with
the  Student’s  t-test.  Variables  without  normal  distribution
were  studied  with  the  Wilcoxon  test.  Categorical  data  were
compared  using  Chi-square  test  or  Fisher’s  exact  test  when
necessary  (SAS,  version  8,  signiﬁcance  with  p  <  0.05).
w
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esults
f  the  68  patients  enrolled,  37  were  being  followed  with
 diagnosis  of  COPD  and  31,  of  extensive  bronchiectasis.
atients  were  diagnosed  with  COPD  if  they  had  chronic  respi-
atory  symptoms  related  to  tobacco  exposure  of  at  least
0  pack-years  (PY),  had  no  history  of  previous  respiratory
isease  before  smoking  and  showed  spirometric  ﬁndings
ompatible  with  the  disease;  a patient  was  diagnosed  with
ronchiectasis  if  he/she  had  never  smoked  or  had  had  a
ong  history  of  chronic  cough  and  sputum  production  which
receded  the  beginning  of  tobacco  use,  with  the  addition
f  abnormal  ﬁndings  on  HRCT  (>2  segments  with  bronchial
ilatations).21 The  majority  of  non-smoker  patients  were
iagnosed  with  bronchiectasis.
Clinical  features,  spirometric  ﬁndings  and  body  composi-
ion  of  the  two  groups  are  shown  in  Table  1.
Among  the  group  with  the  diagnosis  of  bronchiectasis,
here  were  ten  patients  with  atypical  cystic  ﬁbrosis  (adults,
ith  late  diagnosis  and  two  abnormally  elevated  sweat
hloride  concentrations),  two  with  residual  lesions  from
uberculosis,  one  with  alpha-1-antitrypsin  deﬁciency,  one
ith  a  history  of  occupational  exposure,  and  18  of  unknown
tiology.
Among  37  COPD  patients  the  CT  scans  showed  some
ype  of  emphysema  in  29  (78.4%),  and  bronchiectasis  in
8  (48.6%).  In  the  group  with  the  diagnosis  of  bronchiec-
asis,  27(87%)  had  bronchial  dilation  in  more  than  three
obes  and  none  were  found  to  have  emphysema  on  HRCT
cans.
Of  37  COPD  patients,  30  were  considered  current
mokers,22 and  seven,  non-smokers  (had  never  smoked  or
moked  less  than  10  PY).  Among  the  non-smokers,  four  had
iffuse  centrilobular  emphysema;  one  patient  reported  a
ifetime  of  passive  smoking;  and  two  patients  had  panlobular
mphysema.
Irrespective  of  the  diagnosis  of  the  COPD,  smokers  and
on-smokers  were  compared  based  on  their  functional  and
adiological  parameters  (Table  2).  In  spirometry,  FVC  and  VC
ere  found  signiﬁcantly  smaller  in  non-smokers  (p  <  0.001),
nd  there  was  no  signiﬁcant  difference  between  smokers
nd  non-smokers  in  FEV1 and  IC.  In  the  assessment  of  BMI,
RC,  SpO2 at  rest,  use  of  LTOT,  6MWD  and  bioimpedance
16  J.  Rezende  Gonc¸alves  et  al.
Table  2  Comparison  between  non-smokers  and  smokers.
Variables  Non-smokers  (n  =  35)  Smokers  (n  =  33)  P
FEV1 <  30%  predicted  13/35  (37.1%)  17/33  (51.5%)  0.2329
Mean FVC  in  %  predicted  ±  sd  47.3  ±  13.5  59.9  ±  14.4  <0.001
Mean VC  in  %  predicted  ±  sd  51.5  ±  13.5  67.3  ±  17.5  <0.001
IC <  80%  predicted  25/35  (71.4%)  21/33  (63.6%)  0.4924
Flattened diaphragm  (lateral  radiographs)a 12/32  (37.5%)  16/25  (64%)  0.047
Centrilobular  emphysemaa 5/35  (14.3%)  25/32  (78.1%)  <0.001
Paraseptal emphysemaa 6/35  (17.1%)  14/32  (43.7%)  0.017
Presence of  bronchiectasis  33/35  (94.3%)  16/33  (48.5%)  <0.001
Air trapping  or  tree  in  bud  or  centrilobular  nodulesb 33/35  (94.3%) 19/33  (57.6%) <0.001
Median number  of  lobes  with  emphysemaa 0.0  (n  =  35) 6.0  (n  =  31) <0.001
Median number  of  lobes  with  bronchiectasis 5.0  (n  =  35) 0.0  (n  =  33) <0.001
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; VC: slow vital capacity; IC: inspiratory capacity.
a The results indicate the presence of the ﬁnding in the group analyzed. The n varies because some radiological techniques for evaluating
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b In expiratory HRCT cuts were not performed in all patients.
ndings  there  was  no  statistically  signiﬁcant  difference
etween  groups.
HRCT  scan  ﬁndings  associated  smoking  with  the  pres-
nce  of  centrilobular  and  paraseptal  emphysema  (p  <  0.001
nd  0.017,  respectively).  More  lobes  were  found  with
ronchiectasis  in  non-smokers  (p  <  0.001)  and  more  lobes
ith  emphysema  in  smokers  (p  <  0.001).  The  signs  of  small
irways  disease  were  more  frequently  found  in  non-smokers
p  <  0.001).
20  patients  met  the  ATS/ERS  criteria  for  volume  respon-
ers  and  7,  for  ﬂow  responders;  by  Paré  et  al.19 29  patients
ould  be  classiﬁed  as  volume  responders  and  4  patients  were
ow  responders,  respectively.  Due  to  the  low  number  of  ﬂow
esponders,  only  the  characteristics  of  volume  responders
nd  non-responders  were  compared.
There  were  18  patients  with  FEV1 <  30%  predicted  among
9  volume  responders  and  12  patients  with  FEV1 <  30%
redicted  among  39  without  volume  response  (p  =  0.010),
dentiﬁed  by  Paré  et  al.19 criteria.
The  analysis  of  the  other  clinical  parameters,  functional
easurements,  radiological  ﬁndings  and  systemic  repercus-
ions  showed  no  statistically  signiﬁcant  difference  between
olume  responders  and  non-responders,  regardless  of  the
riteria  used.
Patients  were  not  compared  by  diagnosis,  COPD  or
ronchiectasis.
iscussion
e  included  in  this  study  patients  with  obstructive  disease,
eﬁned  by  pre-BD  FEV1/FVC  <  70%,  and  pre-BD  FEV1 <  50%
redicted,  with  the  aim  of  evaluating  severely  ill  patients.
n  the  literature  a  European  consensus23 provides  a  prece-
ent  for  our  choice  as  well  as  relevant  recent  studies  that
ave  used  this  criteria.22,24,25
All  subjects  included  in  our  study  had  a  post-BD
EV1/FVC  <  70%  and  a  post-BD  FEV1 <  80%  predicted,  which
s  in  accordance  with  GOLD  diagnostic  criteria  for  COPD.26
Normal  spirometry  values  following  BD  were  an  exclu-
ion  criterion  and  therefore  asthmatic  patients  were  not
ncluded.  It  was  known  beforehand  that  the  two  diseases
a
e
rhat  would  show  up  in  this  series  of  patients  would  be  COPD
nd  bronchiectasis,  which  do  have  several  characteristics  in
ommon,  such  as  obstruction  not  fully  reversible  with  BD.
In  our  study,  patients  were  considered  smokers  if  they
ad  smoked  more  than  10  PY.22
The  comparison  of  smokers  and  non-smokers  with  the
ame  degree  of  lung  function  compromise  (FEV1)  showed
hat  there  were  few  differences  between  the  groups.  There
as  overlap  in  all  clinical  and  functional  parameters,  except
or  VC  and  FVC  which  were  signiﬁcantly  smaller  in  non-
mokers.  When  systemic  effects  were  assessed  (BMI,  the
atio  LM/FM  and  6MWT)  smoking  did  not  affect  the  results
Table  2).
On  HRCT  scans,  signs  of  small  airway  disease  were  more
requently  found  in  non-smokers  (94.3%  of  the  patients,
 <  0.001).  This  ﬁnding  ﬁts  in  with  the  hypothesis  that  bron-
hiolitis  affecting  the  airways  of  under  2  mm  in  diameter  is
 central  event  in  the  pathogenesis  of  bronchiectasis.27
Signs  of  small  airway  involvement  were  also  frequent  in
mokers  and  were  found  on  HRCT  scans  in  57.6%  of  them.
In  1950,  Reid27 published  a  cornerstone  study  on  the
athology  of  extensive  bronchiectasis.  One  of  the  most
mportant  ﬁndings  was  the  reduction  of  bronchial  subdivi-
ions  between  the  hilum  and  the  periphery  of  the  lung.
he  missing  bronchi,  whenever  their  remnants  could  be
dentiﬁed,  were  obliterated  by  ﬁbrous  tissue  and  all  the  gen-
rations  of  bronchi  and  small  airways  that  should  arise  from
hem  had  completely  disappeared.
Hansell  et  al.28 suggest  that  bronchiolitis  is  the  initial
esion  in  bronchiectasis.
Roberts  et  al.21 evaluated  the  presence  of  airﬂow
bstruction  in  100  patients  with  bronchiectasis  and  also
ound  that  the  presence  and  severity  of  airﬂow  obstruction
orrelated  with  the  intensity  of  mosaic  attenuation  detected
n  HRCT.
In  patients  with  clinical  diagnosis  of  COPD  in  our  study
ronchiectasis  was  seen  in  the  scans  of  18  subjects  (48.6%), ﬁnding  that  is  consistent  with  the  literature  in  patients  of
quivalent  severity  of  airway  obstruction.29--31
Taking  all  this  into  account  the  hypothesis  that  smoking
elated  chronic  bronchitis  and  bronchiectasis  share  many
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2Similarities  and  differences  between  smoker  and  non-smoke
pathogenic  events  is  not  farfetched.  In  fact,  according  to
Boucher,32 there  are  three  well  known  causes  of  chronic
bronchitis:  two  of  them,  cystic  ﬁbrosis  and  primary  ciliary
diskynesia,  are  genetically  determined,  and  one  is  acquired
after  birth  by  those  individuals  who  are  susceptible,  and  is
most  commonly  related  to  tobacco  exposure.  All  three  con-
ditions  compromise  the  mucociliary  transport  apparatus  and
during  their  course  they  all  may  lead  to  bronchiectasis.
Considering  the  pattern  of  response  to  bronchodilator  in
patients  with  severe  obstruction,  an  important  ﬁnding  was
that  using  both  criteria  (ATS/ERS18 and  Paré  et  al.19)  fewer
individuals  were  considered  volume  responders  by  ATS/ERS
criteria.
What  distinguishes  Paré  et  al.19 criteria  is  the  fact  that
they  do  not  refer  to  absolute  values;  a  variation  of  12%  in  FVC
and  FEV1 is  sufﬁcient  for  the  classiﬁcation  of  an  individual  as
a  volume  or  ﬂow  responder.  For  patients  like  the  ones  in  this
study,  with  baseline  volumes  that  are  very  low,  ‘‘small’’  vol-
ume  variation  may  represent  a  large  variation  in  percentage,
without  reaching  the  200  ml  required  by  ATS/ERS.18
As  expected,  ﬂow  response  was  not  signiﬁcant  in  our
sample  of  patients  with  severe  bronchial  obstruction.
In  addition  to  detecting  a  larger  number  of  volume
responder  patients,  Paré  et  al.19 criteria  allowed  the
demonstration  of  an  association  between  the  severity  of
obstructive  disease,  as  assessed  by  FEV1,  and  the  volume
response  (18  patients  with  FEV1 <  30%  among  29  volume
responders  and  12  patients  with  FEV1 <  30%  among  39  with-
out  volume  response,  p  =  0.010).
Schermer  et  al.12 analyzing  BD  response  in  2210  COPD
patients  found  a  positive  correlation  between  FEV1 and
CVF  with  each  stage:  FEV1 declined  toward  the  most
severe  GOLD  stages,  while  CVF  augmented.  These  ﬁnd-
ings  are  in  agreement  with  ours,  provided  that  Paré  et  al.19
criteria  are  applied  to  the  sample.
Conclusions
In  patients  with  severe  obstruction  the  smoking  etiology
does  not  appear  to  be  relevant  in  determining  systemic
complications  such  as  hypoxemia,  exercise  capacity  and  loss
of  lean  body  mass.  Bronchiectasis  was  found  in  a  signiﬁcant
proportion  of  patients  with  severe  COPD.
Volume  response  is  more  common  than  ﬂow  response  in
patients  with  severe  obstruction.  The  comparison  of  two
criteria  for  assessing  bronchodilator  response  showed  that
Paré  et  al.  criteria  are  more  sensitive  than  ATS/ERS  criteria
in  identifying  volume  response  in  this  subgroup  of  patients.
Further  studies  with  a  larger  number  of  patients  might  con-
ﬁrm  our  ﬁndings.
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